- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03159351
The Antidepressant Effects of rTMS After Ischemic Stroke
January 16, 2018 updated by: Zhujiang Hospital
Repetitive Transcranial Magnetic Stimulation for Depression After Basal Ganglia Ischemic Stroke: a Multicenter, Randomized, Double-blind, Placebo-controlled Trial
This is a multicenter, randomized, double-blind, placebo-controlled trial aims to assess the effectiveness of repetitive transcranial magnetic stimulation(rTMS) in treating depression after basal ganglia ischemic stroke and to examine whether such effects are related to restoration of white matter integrity.Sixty-six participants will be recruited from three centers and randomized with a 1:1 ratio to receive active rTMS treatment or sham rTMS treatment in addition to routine supportive treatments.The data of neuropsychological tests and MRI will be collected at 0, 2 and 4 weeks after the commencement of the treatment.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
This is a multicenter, randomized, double-blind, placebo-controlled trial aims to assess the effectiveness of rTMS in treating depression after basal ganglia ischemic stroke and to examine whether such effects are related to restoration of white matter integrity.Sixty-six participants will be recruited from three centers and randomized with a 1:1 ratio to receive active rTMS treatment or sham rTMS treatment in addition to routine supportive treatments.The data of neuropsychological tests and MRI will be collected at 0, 2 and 4 weeks after the commencement of the treatment.The primary outcome is the measurement of 24-item Hamilton Depression Rating Scale (HAMD-24) scores, and the secondary outcomes include diffusion tensor imaging (DTI) results and the results of neuropsychological tests including National Institutes of Health Stroke Scale (NIHSS), Activities of Daily Living Scale (ADLs), Montreal Cognitive Assessment (MoCA),Clinical Global Impressions scales(CGI), Aphasia Battery in Chinese (ABC), Social Support Revalued Scale (SSRS) and Medical Coping Questionnaire (MCMQ).
Study Type
Interventional
Enrollment (Anticipated)
66
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Lianxu Zhao, M.D
- Phone Number: 020-62783082
- Email: zhaolianxu@smu.edu.cn
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510282
- Recruiting
- Zhujiang Hospital
-
Contact:
- Lianxu Zhao, M.D
- Phone Number: +86 13794419610
- Email: zhaolianxu@smu.edu.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
25 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- First-time ischemic stroke with clinical and MRI or CT findings of basal ganglia ischemic stroke and a diagnosis of depression due to stroke based on The Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) and The International Classification of Diseases-10 (ICD-10-CM code 293.83[F06.32]);
- Aged 25-75 years with a recent (from 3 weeks to 3 months) ischemic stroke;
- Clear signs of neurological deficits in the acute phase;
- Clear consciousness;
- Right-handedness.
Exclusion Criteria:
- Aphasia or severe cognitive impairment, severe hearing impairment, or severe language comprehension deficits due to other causes;
- Other cerebral diseases such as Parkinson's disease, encephalitis, dementia, multiple sclerosis, head injury, ect.;
- Severe systemic disease or ongoing neoplasia;
- Ongoing post-operative recovery;
- Prior history of depressive disorders or major trauma within 1 year, severe depression or any other severe mental disorders;
- Current or prior antidepressant use for any reason;
- Addiction to drugs, alcohol or other substances;
- Contraindications of MRI scan and rTMS treatment such as pacemaker implantation, a history of epilepsy, major head trauma, and seizures, ect;
- Pregnant or breast-feeding women;
- Participation in other clinical research projects;
- Refusal to sign informed consent of this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: active rTMS treatment
received active rTMS treatment 20 times for 20 days
|
active rTMS treatment protocol parameters: localization of left DLPFC: frequency=10 Hz, intensity=110% motor threshold(MT), times per train=200 seconds, trains=10, duration= 40 seconds, total times=20;localization of right DLPFC: frequency=1 Hz, intensity=100%MT, times per train=30 seconds, trains=10, duration= 10 seconds, total times=20.
|
Sham Comparator: sham rTMS treatment
received sham rTMS treatment 20 times for 20 days
|
sham rTMS treatment protocol parameters: sham rTMS treatment in the localization of left DLPFC and right DLPFC for 30 minutes,total times=20.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
response rate
Time Frame: baseline, 2nd and 4th week
|
Compare the HAMD-24 scores from baseline to the end of the treatment.the
response to treatment is defined as at least a 50% reduction of the HAMD-24 total score with a final HAMD-24 score below 9.
The response rate is defined as the percentage of number of response.
|
baseline, 2nd and 4th week
|
remission rate
Time Frame: baseline, 2nd and 4th week
|
Compare the HAMD-24 scores from baseline to the end of the treatment.
The remission is defined as a reduction of the HAMD-24 total score by at least 50% from the baseline.
The remission rate is defined as the percentage of number of remission.
|
baseline, 2nd and 4th week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
DTI results of FA
Time Frame: baseline and 4th week
|
DTI parameters including the fractional anisotropy (FA), apparent diffusion coefficient (ADC), neural fiber number (NFN).
Get the change of FA by Comparing the change of FA from baseline to the end of the treatment in each group.
|
baseline and 4th week
|
DTI results of ADC
Time Frame: baseline and 4th week
|
DTI parameters including the fractional anisotropy (FA), apparent diffusion coefficient (ADC), neural fiber number (NFN).
Get the change of ADC by Comparing the change of ADC from baseline to the end of the treatment in each group.
|
baseline and 4th week
|
DTI results of NFN
Time Frame: baseline and 4th week
|
DTI parameters including the fractional anisotropy (FA), apparent diffusion coefficient (ADC), neural fiber number (NFN).
Get the change of NFN by Comparing the change of NFN from baseline to the end of the treatment in each group.
|
baseline and 4th week
|
Neuropsychological tests results of NIHSS
Time Frame: baseline and 4th week
|
Neuropsychological tests including National Institutes of Health Stroke Scale (NIHSS), Activities of Daily Living Scale (ADLs), Montreal Cognitive Assessment (MoCA), Aphasia Battery in Chinese (ABC), Social Support Revalued Scale (SSRS) and Medical Coping Questionnaire score (MCMQ).
Get the change of the result of NIHSS by Comparing the change of NIHSS scores from baseline to the end of the treatment in each group.
|
baseline and 4th week
|
Neuropsychological tests results of ADLs
Time Frame: baseline and 4th week
|
Neuropsychological tests including National Institutes of Health Stroke Scale (NIHSS), Activities of Daily Living Scale (ADLs), Montreal Cognitive Assessment (MoCA), Aphasia Battery in Chinese (ABC), Social Support Revalued Scale (SSRS) and Medical Coping Questionnaire score (MCMQ).
Get the change of the result of ADLs by Comparing the change of ADLs scores from baseline to the end of the treatment in each group.
|
baseline and 4th week
|
Neuropsychological tests results of MoCA
Time Frame: baseline and 4th week
|
Neuropsychological tests including National Institutes of Health Stroke Scale (NIHSS), Activities of Daily Living Scale (ADLs), Montreal Cognitive Assessment (MoCA), Aphasia Battery in Chinese (ABC), Social Support Revalued Scale (SSRS) and Medical Coping Questionnaire score (MCMQ).
Get the change of the result of MoCA by Comparing the change of MoCA scores from baseline to the end of the treatment in each group.
|
baseline and 4th week
|
Neuropsychological tests results of ABC
Time Frame: baseline and 4th week
|
Neuropsychological tests including National Institutes of Health Stroke Scale (NIHSS), Activities of Daily Living Scale (ADLs), Montreal Cognitive Assessment (MoCA), Aphasia Battery in Chinese (ABC), Social Support Revalued Scale (SSRS) and Medical Coping Questionnaire score (MCMQ).
Get the change of the result of ABC by Comparing the change of ABC scores from baseline to the end of the treatment in each group.
|
baseline and 4th week
|
Neuropsychological tests results of SSRS
Time Frame: baseline and 4th week
|
Neuropsychological tests including National Institutes of Health Stroke Scale (NIHSS), Activities of Daily Living Scale (ADLs), Montreal Cognitive Assessment (MoCA), Aphasia Battery in Chinese (ABC), Social Support Revalued Scale (SSRS) and Medical Coping Questionnaire score (MCMQ).
Get the change of the result of SSRS by Comparing the change of SSRS scores from baseline to the end of the treatment in each group.
|
baseline and 4th week
|
Neuropsychological tests results of MCMQ
Time Frame: baseline and 4th week
|
Neuropsychological tests including National Institutes of Health Stroke Scale (NIHSS), Activities of Daily Living Scale (ADLs), Montreal Cognitive Assessment (MoCA), Aphasia Battery in Chinese (ABC), Social Support Revalued Scale (SSRS) and Medical Coping Questionnaire score (MCMQ).
Get the change of the result of MCMQ by Comparing the change of MCMQ scores from baseline to the end of the treatment in each group.
|
baseline and 4th week
|
Neuropsychological tests results of CGI
Time Frame: baseline and 4th week
|
Neuropsychological tests including Clinical Global Impressions scales
|
baseline and 4th week
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 20, 2017
Primary Completion (Anticipated)
May 31, 2020
Study Completion (Anticipated)
May 31, 2020
Study Registration Dates
First Submitted
May 1, 2017
First Submitted That Met QC Criteria
May 16, 2017
First Posted (Actual)
May 18, 2017
Study Record Updates
Last Update Posted (Actual)
January 18, 2018
Last Update Submitted That Met QC Criteria
January 16, 2018
Last Verified
January 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2016-SJNK-005
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Post-stroke Depression
-
University of CincinnatiRecruitingPost-stroke DepressionUnited States
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...RecruitingHealthy | Post-stroke DepressionChina
-
Chinese University of Hong KongResearch Grants Council, Hong KongRecruiting
-
Maastricht University Medical CenterCompletedVascular Dementia | Post-stroke Depression | Vascular Cognitive Impairment | Post-stroke Apathy | Post-stroke DementiaNetherlands
-
University Hospital of North NorwayNorwegian Extra Foundation for Health and RehabilitationCompletedStroke | Quality of Life | Fatigue | Cognitive Impairment | Post-stroke Depression | Neuropsychology | Post-Stroke Fatigue | Meta-cognitionNorway
-
University Medicine GreifswaldCompletedPost-stroke Depression | Post-stroke AphasiaGermany
-
The Third Affiliated hospital of Zhejiang Chinese...Hangzhou Hospital of Traditional Chinese Medicine; Zhejiang General Hospital... and other collaboratorsRecruiting
-
Kibi International UniversityUnknown
-
Xuanwu Hospital, BeijingUnknownPost-stroke DepressionChina
-
China Academy of Chinese Medical SciencesRecruitingPost-stroke DepressionChina
Clinical Trials on active rTMS treatment
-
Changping LaboratoryRecruitingObsessive-Compulsive Disorder | OCDChina
-
Changping LaboratoryNot yet recruitingMajor Depressive Disorder | Treatment Resistant DepressionChina
-
Changping LaboratoryWest China Hospital; The Second Affiliated Hospital of Xinxiang Medical University and other collaboratorsRecruitingMajor Depressive Disorder | Treatment Resistant DepressionChina
-
Changping LaboratoryNot yet recruitingObsessive-Compulsive Disorder | OCD
-
University of ManitobaUnknownAlzheimer's DiseaseCanada, Australia
-
Wave NeuroscienceCompleted
-
Wave NeuroscienceTexas A&M University; GilpinPhillips BIOMED, LLC; Peachtree BioResearch SolutionsRecruitingTraumatic Brain Injury | PostTraumatic Stress Disorder | Postconcussive SymptomsUnited States
-
New York State Psychiatric InstituteSuspended
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
Centre Hospitalier Universitaire de Saint EtienneCompleted